Current position

Two Sigma Investments, LP’s Jazz Pharmaceuticals Plc (JAZZ) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Two Sigma Investments, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2015Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares461.38KHighest verified quarter-end share count
Quarters reported12Verified quarters with shares above zero
What happened?

Two Sigma Investments, LP first reported Jazz Pharmaceuticals Plc in Q4 2015. The reported position was increased and reduced across later filings. Two Sigma Investments, LP currently reports 400.21K shares. The latest verified filing showed: Bought 1,941.9% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 1,941.9% more+380.61K shares · 400.21K shares reported after the change
Filing context

Quarter-end price $240.97

Q2 2025
Sold 86.9% of the position−299.30K shares · 45.11K shares remained
Filing context

Quarter-end price $106.12

Q1 2025
Bought 84.1% more+157.29K shares · 344.41K shares reported after the change
Filing context

Quarter-end price $124.15

Q3 2024
Bought 242.7% more+226.71K shares · 320.11K shares reported after the change
Filing context

Quarter-end price $111.41

Q1 2023
Sold 64.2% of the position−153.78K shares · 85.79K shares remained
Filing context

Quarter-end price $146.33

Q4 2022
Bought 615.1% more+206.07K shares · 239.57K shares reported after the change
Filing context

Quarter-end price $159.31

Portfolio importance

How important is Jazz Pharmaceuticals Plc in Two Sigma Investments, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#318of 5017 reported positions
Peak portfolio weight0.3%Q2 2016
Best historical rank#75Q2 2016
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$243.592026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$240.97Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Two Sigma’s complete trading book, models, short positions, exact trade dates or execution prices. Options are reported separately.